H.R. 2918 · 115th Congress
Patients First Act of 2017
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 115th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
BanksSponsor33 cosponsors · 1 D, 32 R
D
Lipinski
TF
R
Franks
LM
R
Messer
AH
R
Harris
TR
R
Rokita
JD
R
Duncan
PO
R
Olson
BH
R
Huizenga
TC
R
Cole
TK
R
Kelly
MM
R
Meadows
RM
R
Marshall
DR
R
Ross
PR
R
Roskam
GB
R
Bilirakis
DL
R
Lamborn
GG
R
Grothman
FR
R
Rooney
KR
R
Rothfus
RN
R
Norman
TG
R
Graves
TM
R
Murphy
JF
R
Fortenberry
BB
R
Babin
TB
R
Budd
LG
R
Gohmert
GH
R
Harper
DL
R
LaMalfa
RW
R
Weber
CS
R
Smith
BC
R
Carter
MJ
R
Johnson
SR
R
Russell1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill amends the Public Health Service Act to require the Department of Health and Human Services (HHS) to conduct and support basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of, or treatments for, diseases and other…
What it does: CRS summary · Introduced in House · Jun 15, 2017
Patients First Act of 2017
This bill amends the Public Health Service Act to require the Department of Health and Human Services (HHS) to conduct and support basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of, or treatments for, diseases and other adverse health conditions, provided that the techniques will not involve: (1) the creation of a human embryo for research purposes; (2) the destruction or discarding of, or risk of injury to, a living human embryo; or (3) the use of any stem cell the derivation or provision of which would be inconsistent with this bill.
HHS must issue guidelines to ensure that any research (including any clinical trial) supported under this bill: (1) is clearly consistent with the standards established in this bill, if conducted using human cells; and (2) is prioritized in terms of potential for near-term clinical benefit in human patients.
HHS must report on peer reviewed stem cell research proposals that were not funded.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Patients First Act of 2017
Latest action (Jun 16, 2017): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Jun 15, 2017
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.